U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458347) titled 'A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation' on March 03.
Brief Summary: The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
KRAS-mutant Colorectal Cancer (CRC)
Other KRAS-mutant Solid Tumors
Intervention:
D...